We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Lead Author: Sabrina Paganoni, MD, PhD
Published: New England Journal of Medicine
Date: September 3, 2020
Clinical Trial Design for a Phase II, Randomized Placebo-Controlled Trial of AMX0035 in Alzheimer’s Disease
Lead Author: Kent L. Leslie
Published: Alzheimer’s Association International Conference (AAIC)
Date: July 24, 2018
Clinical Trial Design for a Phase II, Randomized, Placebo-Controlled Trial of AMX0035 in Amyotrophic Lateral Sclerosis (CENTAUR)
Lead Author: Joshua Cohen, Co-CEO and Co-Founder, Amylyx Pharmaceuticals
Published: International Symposium on ALS-MND (MNDA)
Date: December 9, 2017
Evaluation of AMX0035, a Novel Combination Therapy for the Treatment of Neurodegenerative Diseases, in Cellular Models of Friedreich’s Ataxia
Lead Author: Kent L. Leslie
Published: International Ataxia Research Conference
Date: September 29, 2017
AMX0035, a Novel Combination Therapeutic Candidate for Treatment of Primary Mitochondrial Diseases
Lead Author: Kent L. Leslie
Published: United Mitochondrial Disease Foundation Mitochondrial Medicine
Date: June 29, 2017